Recent Press Releases

Scientific Clinical | Nanobiotix announces plan for global phase III Head and Neck cancer registration trial along with overall development update
Corporate | Nanobiotix receives the 2019 Prix Galien award for first-in-class Hensify
Scientific Clinical | Nanobiotix announces new results from pre-clinical immuno-oncology study at SITC 2019

ALL NANOBIOTIX PRESS RELEASE

Discover all
Overview_News_1


NBTXR3 First in Class Radioenhancer

Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.

Only one administration

Fits into existing standard of care :

  • No change in equipment
  • No change in current patient flow
  • No change in protocol

    • One product addressing areas of high unmet medical needs.


    See more

    Events

    Meet Nanobiotix International events and conferences

    Discover all
    January 13-16

    J.P. Morgan 38th Healthcare Conference

    More info
    February 27-29

    Multidisciplinary Head & Neck cancer Symposium

    More info

    JOIN US


    "Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life."

    Anne-Juliette Hermant
    Chief People Officer
    BECOME A LIFE EXPANDER
     

    Download our latest
    Corporate Presentation

     
    English